Table 3 Comparison of demographics of patients receiving different treatments stratified by nomogram points in the propensity model
Nomogram points/Absolute difference in propensity score of matched pairs | 3–4.2 (n = 30)/< 0.0001 |  | 6.7–10 (n = 174)/0.0007 |  | 11.9–13 (n = 224)/0.0007 |  | 15.2–18 (n = 90)/< 0.0001 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | SR/Ablation/ TACE/ Transplant (n = 15) | Targeted/ Supportive (n = 15) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 87) | Targeted/ Supportive (n = 87) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 112) | Targeted/ Supportive (n = 112) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 45) | Targeted/ Supportive (n = 45) | P/Stddiff |
Age | 75 ± 13 | 72 ± 10 | 0.92/0.14 | 63 ± 14 | 65 ± 14 | 0.21/0.18 | 63 ± 15 | 64 ± 14 | 0.06/0.3 | 59 ± 14 | 61 ± 13 | 0.094/0.16 |
Male (%) | 13 (87) | 14 (93) | 1/0.14 | 65 (75) | 66 (76) | 0.86/0.18 | 84 (75) | 93 (83) | 0.14/0.3 | 35 (78) | 39 (87) | 0.27/0.61 |
HBV (%) | 6 (40) | 4 (27) | 0.7/0.29 | 47 (54) | 48 (55) | 0.88/0.02 | 64 (57) | 65 (58) | 0.89/0.02 | 30 (67) | 21 (47) | 0.056/0.41 |
HCV (%) | 5 (33) | 7 (47) | 0.46/0.27 | 27 (31) | 22 (25) | 0.4/0.13 | 19 (17) | 23 (21) | 0.49/0.09 | 9 (20) | 13 (29) | 0.327/0.21 |
Alcoholism (%) | 2 (13) | 2 (13) | 1/0 | 10 (11) | 13 (15) | 0.5/0.1 | 28 (25) | 32 (29) | 0.55/0.08 | 11 (24) | 14 (31) | 0.48/0.15 |
CTP class A (%) | 15 (100) | 14 (93) | 1/0.38 | 72 (83) | 74 (85) | 0.68/0.06 | 85 (76) | 80 (81) | 0.45/0.1 | 0 | 0 | N/A |
Ascites (%) | 2 (13) | 2 (13) | 1/0 | 15 (17) | 18 (21) | 0.56/0.09 | 37 (33) | 41 (37) | 0.58/0.08 | 29 (64) | 34 (76) | 0.25/0.24 |
eGFR > 60 (ml/min/1.73m2) | 5 (33) | 5 (33) | 1/0 | 62 (71) | 65 (75) | 0.61/0.08 | 83 (74) | 79 (71) | 0.55/0.08 | 37 (82) | 33 (73) | 0.311/0.22 |
Tumor > 5 cm | 6 (40) | 6 (40) | 1/0 | 66 (76) | 65 (75) | 0.86/0.03 | 96 (86) | 99 (88) | 0.55/0.08 | 34 (76) | 34 (76) | 1/0 |
Single tumor (%) | 11 (73) | 8 (53) | 0.26/0.42 | 56 (64) | 47 (54) | 0.17/0.21 | 57 (51) | 50 (45) | 0.35/0.13 | 23 (51) | 21 (47) | 0.673/0.09 |
Tumor burden 0/1/2/3 | 7/53/40/0 | 13/40/47/0 | 0.67/0.31 | 2/13/28/57 | 3/9/29/59 | 0.87/0.13 | 0/0/24/76 | 0/0/29/71 | 0.45/0.13 | 0/0/0/100 | 0/0/0/100 | N/A |
Performance status 0/1/2 (%) | 40/40/20 | 47/33/20 | 0.9/0.15 | 60/22/18 | 62/23/15 | 0.83/0.09 | 0/71/29 | 0/71/29 | 1/0 | 29/47/24 | 20/40/40 | 0.266/0.35 |
Vascular invasion (%) | 0 | 0 | N/A | 47 (54) | 49 (56) | 0.76/0.05 | 72 (64) | 71 (63) | 0.89/0.02 | 37 (82) | 37 (82) | 1/0 |
Metastasis/lymph node (%) | 0 | 0 | N/A | 8 (9) | 9 (10) | 0.8/0.04 | 26 (23) | 31 (28) | 0.44/0.1 | 13 (29) | 21 (47) | 0.08/0.37 |
AFP > 400 ng/mL | 3 (20) | 3 (20) | 1/0 | 44 (51) | 42 (48) | 0.76/0.05 | 65 (58) | 61 (54) | 0.59/0.07 | 22 (49) | 28 (62) | 0.203/0.27 |
Diabetes mellitus (%) | 7 (47) | 6 (40) | 0.71/0.13 | 18 (21) | 20 (23) | 0.71/0.06 | 32 (29) | 39 (35) | 0.31/0.13 | 9 (20) | 9 (20) | 1/0 |